AI assistant
Ipsen — Regulatory Filings 2013
Dec 23, 2013
1449_iss_2013-12-23_7d0c42b1-ab90-4ed4-85a8-78c6c1bccaf2.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Ipsen announces its corporate agenda for 2014
Paris (France), 23 December 2013 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced its corporate agenda* for 2014:
| 28 January 2014: |
Full year 2013 sales |
|---|---|
| 28 February 2014: |
Full year 2013 results |
| 30 April 2014: |
First quarter 2014 sales |
| 4 June 2014: |
General shareholders' meeting |
| 12 June 2014: |
Payment of 2013** dividend |
| 29 August 2014: |
First half 2014 sales & results |
| 29 October 2014: |
First nine months 2014 sales |
* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary
** Pending approval of the Board of directors (27th February 2014) and of the General shareholders' meeting (4th June 2014)
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totalled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
For further information:
Media Didier Véron Senior Vice-Président, Public Affairs and Communication Tel.: +33 (0)1 58 33 51 16 Fax: +33 (0)1 58 33 50 58 E-mail: [email protected]
Brigitte Le Guennec Media and Public Relations Officer Tel.: +33 (0)1 58 33 51 17 Fax: +33 (0)1 58 33 50 58 E-mail : [email protected]
Financial Community
Pierre Kemula Vice President, Corporate Finance, Treasury and Financial Markets Tel.: +33 (0)1 58 33 60 08 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]
Stéphane Durant des Aulnois
Investor Relations Officer Tel.: +33 (0)1 58 33 60 09 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]
Thomas Peny-Coblentz
Investor Relations Manager Tel.: +33 (0)1 58 33 56 36 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]